BridgeBio Oncology Therapeutics (BBOT) executive compensation, 2026 proxy

Eli Wallace, Ph.D., Former President and Chief Executive Officer, was paid $11.5M in 2025, up 157% from $4.5M the year before.

Filed
April 28, 2026
Annual meeting
June 16, 2026
Pay year
2025
Named executives
3
CEO total pay
$11.5M+157% vs prior year
CEO 2025 Total Pay
$11,489,545Up from $4,463,320 in 2024
Milestone Cash Bonus
$3,000,000Earned upon business combination transaction
Corporate Achievement Rate
105%Of target for annual bonus
CFO Signing Bonus
$75,000Paid to Uneek Mehra

How Ph.D. was paid

$11.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary5%Bonus2%Option awards67%Non-equity incentive26%All other compensation0%

Named executive officers

ExecutiveTotal
Eli Wallace, Ph.D.Former President and Chief Executive Officer$11,489,545
Uneek Mehra, M.B.A.Former Chief Financial Officer$4,555,625
Yong Ben, M.D., M.B.A.Chief Medical and Development Officer$3,227,364

What changed and why

  • $11.5MFormer CEO Eli Wallace received $11,489,545 in total compensation for 2025, an increase from $4,463,320 in 2024.
  • 105%Corporate performance objectives for the annual bonus were achieved at 105% of target.
  • $3MDr. Wallace earned a $3,000,000 milestone bonus upon completion of the business combination transaction in August 2025.
  • $75,000Uneek Mehra commenced employment as Chief Financial Officer on July 21, 2025, receiving a $75,000 signing bonus.
  • Option awards constituted the largest component of equity compensation for named executive officers in 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.